Fundraising Fox
16 people tracked
Also known as Palo Santo
Find your way into Palo Santo VC
2,343 people in our graph share verified history with the Palo Santo VC team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Palo Santo backs next-generation neuroscience companies advancing breakthrough therapeutics and technologies for mental health, spanning discovery through clinical translation. Its portfolio concentrates on drug discovery platforms, psychedelic and serotonergic pharmaceuticals, neurotechnology, and mental health treatment services aimed at neurological and psychiatric disorders.
Source: firm website, verified Sep 27, 2026.
Team · 16 people
from the firm's website & public directories
Founder mafia
3 people who came through Palo Santo VC went on to found or lead other companies.
What they invest in
from 20 of 30 portfolio companiesBiotech ×18Digital Health ×13Healthtech ×9Mental Health ×8Deep Tech ×6Medical Devices ×6AI & Machine Learning ×4EdTech ×1
HQs:United States×10Canada×1
Investments · 30 tracked
founders shown can be your intro pathBy year:2024 · 12022 · 12021 · 42019 · 17 dated
2AB BioscienceS develops first-in-class small molecule therapeutics targeting the 5-HT2A receptor for ophthalmology and central nervous system disorders.
BiotechDeep TechDigital HealthEdTechHealthtechMedical DevicesSanta Monica, US
Alex Speiser(Co-Founder & Chief Executive Officer)inCharles Nichols, PhD(Co-Founder & Chief Science Officer)David Nichols, PhD(Co-Founder & Head of Chemistry)Tim Foster, PhD(Co-Founder & Head of Translational Discovery)
BoardGopal Das(Director)
Co-investorsLIONHEART VENTURESWhat If Ventures
AtaiBeckley develops rapid-acting and durable mental health treatments for patients with difficult-to-treat mental health conditions.
BiotechMedical DevicesMental Health
Christian AngermayerCosmo Feilding Mellen(Founder)inSrinivas Rao
Co-investorsFJ LabsIter InvestmentsLeafy TunnelNoeticRedbus VenturesWhat If Ventures+1 more
BRC Therapeutics develops and manufactures botanically-derived pharmaceutical products, with expertise spanning drug development and manufacturing for pharmaceutical applications.
BiotechDigital HealthHealthtechMedical Devices
George Hodgin(Founder and CEO)inCharles Schumacher
Co-investorsDelta Emerald Ventures
Bright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform.
BiotechDeep TechHealthtechNew York, US
Alan Kozikowski(Executive Officer, Director)inIan McDonaldRyan Cheung(Chief Financial Officer)JAN PEDERSEN(Chief Science Officer)Gideon Shapiro(Executive Officer)Revati Sheeniwas(Executive Officer)
Co-investorsLifeSci Venture PartnersPsyMed Ventures
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalDolby Family VenturesNoeticOMX VenturesPsyMed Ventures+6 more
Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds.
BiotechHealthtechMental HealthToronto, CA
Judy Blumstock(Chief Executive Officer, Founder, Director)inMichael B. McDonnell(Chief Medical Officer)Grant McCutcheon(Chief Financial Officer)in
Co-investorsJLSNoeticNew Enterprise Associates (NEA)Nextech InvestRA Capital
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.
AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US
Linda Goodman(Founder)inAshley(CEO)
Co-investorsage1Farvatn VentureGRIDS CapitalLifeforce CapitalMetaplanetVibe Capital+4 more
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.
AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US
Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inJONATHAN SPORN(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Jonathan Sporn, M.D.(President and Chief Executive Officer)in
Co-investorsAera VCFrontera Technology VenturesFrontier Path VCJames Beshara FundJLSMagnetic Ventures+10 more
Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.
Digital HealthMedical DevicesMental Health
Jonathan Sabbagh(Co-founder & Executive Chairman of the Board)inMyriam Barthes(Co-founder & CEO)in
Co-investorsAble PartnersAlleyCorpCoalition OperatorsFifty YearsMantis CapitalPROOF+8 more
Kadence Bio is a clinical-stage life sciences company developing therapeutics for conditions in sexual and mental health.
BiotechDigital HealthMental Health
Active seed-stage healthcare company
Eugene, US
Nicholas Allen(Chief Executive Officer)Phillip Scripa(Chief Financial Officer and Secretary)William Shortt(Chief Operating Officer)Jan Hardorp(Director)in
Co-investorsBIP VenturesJLSre.Mind Capital
Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety.
BiotechDeep TechHealthtechAllston, US
Dario Doller(Co-founder)inKevin Hodgetts(Founding Lab / Co-founder)inAndrew Thomson(Executive Officer, Director, Promoter)in
Co-investorsPillar VCHealthspan Capital
MycoMedica Life Sciences is a biopharmaceutical company developing psilocybin-based treatments for mental health and neurodegenerative disorders.
BiotechDigital HealthMental HealthShelton, US
Co-investorsLauder PartnersObvious Ventures
Pangea Bio develops therapies targeting central nervous system and mental health disorders by activating the TrkB receptor pathway to promote neuronal survival and synaptic plasticity.
BiotechDeep TechDigital Health
Co-investorsMetaplanetNO LABEL VENTURESSeaside VenturesVox CapitalXEIA Venture Partners
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Co-investorsFemHealth VenturesMitsui Global InvestmentMPM BioImpactNovo Holdings
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inKevin Lalande(Director)inRichard Simon(Director)
Co-investorsBonaventure Equity, LLCHatteras Venture PartnersIter InvestmentsMission BiocapitalRoute 66 VenturesService Provider Capital+2 more
Syndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's.
AI & Machine LearningBiotechDigital Health
Co-investorsEvolution VC PartnersTenmileCatalio Capital Management
Tactogen develops patented new chemical entities, including benzofuran-based compositions, and conducts preclinical research and publishes data on these compounds.
BiotechDeep TechHealthtech
Matthew Baggott(CEO)in
Co-investorsLeafy TunnelNoeticPsyMed Ventures10X CapitalWefunder
Transcend Therapeutics develops rapid-acting pharmaceutical treatments for neuropsychiatric diseases, including PTSD and depression, targeting patients unresponsive to current psychiatric medications.
BiotechDigital HealthMedical DevicesMental Health
Blake Mandell(Co-Founder & CEO)in
Co-investorsAlleyCorpAlpha Wave GlobalEmerald Development ManagersAlley Robotics Ventures
Wavepaths develops adaptive therapeutic music designed to support mental health and wellness practitioners in their sessions.
Digital HealthMental HealthWellness & Fitness
Mendel Kaelen(Founder & CEO)in
Co-investorsMITONReflex CapitalLIONHEART VENTURESNeo Kuma Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
<UNKNOWNatai Life SciencesBeacon BiosignalsBionomicsBlackbox BioCybinFluenceneurocarePsy TherapeuticsXylo
Portfolio news
latest coverage across their companiesKsana Health · prnewswire.com · May 14, 2026
Frequently asked questions
- How many investments has Palo Santo VC made?
- Palo Santo VC has 30 tracked investments.
- What sectors does Palo Santo VC focus on?
- Palo Santo VC focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Mental Health.
Co-investors · 9
Fifty Years (50Y) is a pre-seed and seed-focused venture capital firm that backs founders using technology to solve major global problems, and also helps start companies.
Pioneer Fund is a venture capital firm investing in the top Y Combinator startups.
500 Global (formerly 500 Startups) is a venture capital firm whose flagship Silicon Valley strategy backs promising technology companies from pre-seed onward across a range of sectors and geographies.
Dawn Capital is a European venture capital firm backing companies with global ambitions.
Avalanche is a private investment firm led by Katelyn Donnelly that invests early in technology companies at structural inflection points, pairing capital with operational experience in complex markets like government, energy, and critical infrastructure.
Amino Collective is an early-stage venture firm that backs bold, unconventional founders willing to explore uncharted territory.
Blueyard is a small equal partnership with offices in the US and Europe, investing in early-stage companies.
Cerulean Ventures is a venture capital firm that backs founders using AI to digitize and transform traditionally under-digitized physical-world industries such as manufacturing, supply chains, maritime, food and agriculture, and energy.
Cambridge Angels is a UK business angel network that has been providing capital and operational support to entrepreneurs since 2001, backing more than 150 companies.
Firms observed investing alongside Palo Santo VC, from public investor directories. Shared companies are the overlap with Palo Santo VC's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
JAZZ Venture Partners is a venture capital firm investing in early- and growth-stage companies at the intersection of technology, science, and human performance across enterprise, wellness, healthcare, and consumer markets.
Kaleida Capital is a venture firm investing in neurotechnology, backing founders building brain-inspired technologies at the intersection of neuroscience and artificial intelligence.